D Cunningham

Summary

Affiliation: Institute of Cancer Research
Country: UK

Publications

  1. ncbi request reprint Integrating the oral fluoropyrimidines into the management of advanced colorectal cancer
    D Cunningham
    Department of Medicine, The Royal Marsden Hospital, Downs Road, Surrey SM2 5PT, Sutton, UK
    Eur J Cancer 37:826-34. 2001
  2. ncbi request reprint Optimizing the use of irinotecan in colorectal cancer
    D Cunningham
    Gastrointestinal Unit, The Royal Marsden Hospital, London, Surrey, UK
    Oncologist 6:17-23. 2001
  3. ncbi request reprint New options for outpatient chemotherapy--the role of oral fluoropyrimidines
    D Cunningham
    Department of Medicine, The Royal Marsden Hospital, London, UK
    Cancer Treat Rev 27:211-20. 2001
  4. pmc Oxaliplatin and protracted venous infusion of 5-fluorouracil in patients with advanced or relapsed 5-fluorouracil pretreated colorectal cancer
    I Chau
    Gastrointestinal Unit, Department of Medicine, Royal Marsden Hospital, Downs Road, Sutton, Surrey, SM2 5PT, UK
    Br J Cancer 85:1258-64. 2001
  5. pmc Phase I study of epirubicin, cisplatin and capecitabine plus matuzumab in previously untreated patients with advanced oesophagogastric cancer
    S Rao
    Department of Medicine, Royal Marsden Hospital, Surrey, UK
    Br J Cancer 99:868-74. 2008
  6. doi request reprint The impact of primary tumour origins in patients with advanced oesophageal, oesophago-gastric junction and gastric adenocarcinoma--individual patient data from 1775 patients in four randomised controlled trials
    I Chau
    Department of Medicine, Royal Marsden Hospital, London
    Ann Oncol 20:885-91. 2009
  7. pmc A phase I/II study of leucovorin, carboplatin and 5-fluorouracil (LCF) in patients with carcinoma of unknown primary site or advanced oesophagogastric/pancreatic adenocarcinomas
    A Rigg
    GI Unit, Cancer Research Campaign Section of Medicine, The Royal Marsden Hospital, Institute of Cancer Research, Sutton, Surrey, UK
    Br J Cancer 75:101-5. 1997
  8. doi request reprint A phase II trial evaluating capecitabine and irinotecan as second line treatment in patients with oesophago-gastric cancer who have progressed on, or within 3 months of platinum-based chemotherapy
    Alexandra Leary
    Department of Medicine, Royal Marsden Hospital, Sutton, London, Surrey, UK
    Cancer Chemother Pharmacol 64:455-62. 2009
  9. pmc Report of two protocol planned interim analyses in a randomised multicentre phase III study comparing capecitabine with fluorouracil and oxaliplatin with cisplatin in patients with advanced oesophagogastric cancer receiving ECF
    K Sumpter
    Department of Medicine, Royal Marsden Hospital NHS Trust, Down s Road, Sutton, Surrey SM2 5PT, UK
    Br J Cancer 92:1976-83. 2005
  10. pmc Adjuvant chemotherapy for oesophagogastric cancer with epirubicin, cisplatin and infusional 5-fluorouracil (ECF): a Royal Marsden pilot study
    A Bamias
    Cancer Research Campaign Section of Medicine, Institute of Cancer Research, Surrey, UK
    Br J Cancer 71:583-6. 1995

Collaborators

Detail Information

Publications112 found, 100 shown here

  1. ncbi request reprint Integrating the oral fluoropyrimidines into the management of advanced colorectal cancer
    D Cunningham
    Department of Medicine, The Royal Marsden Hospital, Downs Road, Surrey SM2 5PT, Sutton, UK
    Eur J Cancer 37:826-34. 2001
    ..v.) 5-FU as first-line treatment for metastatic colorectal cancer...
  2. ncbi request reprint Optimizing the use of irinotecan in colorectal cancer
    D Cunningham
    Gastrointestinal Unit, The Royal Marsden Hospital, London, Surrey, UK
    Oncologist 6:17-23. 2001
    ..v. 5-FU as a combination partner for irinotecan...
  3. ncbi request reprint New options for outpatient chemotherapy--the role of oral fluoropyrimidines
    D Cunningham
    Department of Medicine, The Royal Marsden Hospital, London, UK
    Cancer Treat Rev 27:211-20. 2001
    ..In the future, these more convenient, oral fluoropyrimidines may replace intravenous 5-FU in the treatment of breast and colorectal cancer...
  4. pmc Oxaliplatin and protracted venous infusion of 5-fluorouracil in patients with advanced or relapsed 5-fluorouracil pretreated colorectal cancer
    I Chau
    Gastrointestinal Unit, Department of Medicine, Royal Marsden Hospital, Downs Road, Sutton, Surrey, SM2 5PT, UK
    Br J Cancer 85:1258-64. 2001
    ..4% (95% CI = 38.7-73.7%). The median failure-free survival was 4 months. Oxaliplatin and PVI 5FU is an active and well tolerated regimen in patients with heavily pre-treated advanced colorectal cancer...
  5. pmc Phase I study of epirubicin, cisplatin and capecitabine plus matuzumab in previously untreated patients with advanced oesophagogastric cancer
    S Rao
    Department of Medicine, Royal Marsden Hospital, Surrey, UK
    Br J Cancer 99:868-74. 2008
    ..At the doses evaluated in serial skin biopsies, matuzumab decreased phosphorylation of EGFR and MAPK, and increased phosphorylation of STAT-3...
  6. doi request reprint The impact of primary tumour origins in patients with advanced oesophageal, oesophago-gastric junction and gastric adenocarcinoma--individual patient data from 1775 patients in four randomised controlled trials
    I Chau
    Department of Medicine, Royal Marsden Hospital, London
    Ann Oncol 20:885-91. 2009
    ..It is unclear if differential chemotherapy effects exist on overall survival (OS), response rate (RR) and toxicity depending on primary tumour origin [oesophageal versus oesophago-gastric junction (OGJ) versus gastric adenocarcinoma]...
  7. pmc A phase I/II study of leucovorin, carboplatin and 5-fluorouracil (LCF) in patients with carcinoma of unknown primary site or advanced oesophagogastric/pancreatic adenocarcinomas
    A Rigg
    GI Unit, Cancer Research Campaign Section of Medicine, The Royal Marsden Hospital, Institute of Cancer Research, Sutton, Surrey, UK
    Br J Cancer 75:101-5. 1997
    ..The majority of patients described a symptomatic improvement with LCF chemotherapy. The recommended dose of 5-FU for future studies is 350 mg m-2 combined with leucovorin 20 mg m-2 and carboplatin (AUC5)...
  8. doi request reprint A phase II trial evaluating capecitabine and irinotecan as second line treatment in patients with oesophago-gastric cancer who have progressed on, or within 3 months of platinum-based chemotherapy
    Alexandra Leary
    Department of Medicine, Royal Marsden Hospital, Sutton, London, Surrey, UK
    Cancer Chemother Pharmacol 64:455-62. 2009
    ..There is no standard second line therapy for relapsed oesophago-gastric (O-G) cancer...
  9. pmc Report of two protocol planned interim analyses in a randomised multicentre phase III study comparing capecitabine with fluorouracil and oxaliplatin with cisplatin in patients with advanced oesophagogastric cancer receiving ECF
    K Sumpter
    Department of Medicine, Royal Marsden Hospital NHS Trust, Down s Road, Sutton, Surrey SM2 5PT, UK
    Br J Cancer 92:1976-83. 2005
    ..i.d.(-1), which is similar to that observed with F, confirming this to be the optimal dose. The replacement of C by O and F by X does not appear to impair efficacy. The trial continues to total accrual of 1000 pts...
  10. pmc Adjuvant chemotherapy for oesophagogastric cancer with epirubicin, cisplatin and infusional 5-fluorouracil (ECF): a Royal Marsden pilot study
    A Bamias
    Cancer Research Campaign Section of Medicine, Institute of Cancer Research, Surrey, UK
    Br J Cancer 71:583-6. 1995
    ..The results, especially in patients with stage III disease, are encouraging and support the investigation of this regimen within a prospective randomised trial...
  11. doi request reprint A dose escalation study of gemcitabine plus oxaliplatin in combination with imatinib for gemcitabine-refractory advanced pancreatic adenocarcinoma
    N Starling
    Department of Medicine, Royal Marsden Hospital, NHS Foundation Trust, Surrey and London, UK
    Ann Oncol 23:942-7. 2012
    ..This study aimed to define safe doses of gemcitabine plus oxaliplatin when combined with imatinib (potent PDGFR-╬▓ inhibitor) in patients with advanced gemcitabine-refractory pancreatic cancer (PC)...
  12. doi request reprint Two different first-line 5-fluorouracil regimens with or without oxaliplatin in patients with metastatic colorectal cancer
    D Cunningham
    Department of Medicine, Royal Marsden Hospital, London and Surrey, UK
    Ann Oncol 20:244-50. 2009
    ..The aim of this multicentre, open-label, phase IIIb study was to assess the addition of oxaliplatin to two different 5-FU regimens...
  13. pmc High-dose chemotherapy and autologous bone marrow transplant in relapsed Hodgkin's disease--a pragmatic prognostic index
    S Milan
    Cancer Research Campaign, Section of Medicine, Sutton, Surrey, UK
    Br J Cancer 73:1272-7. 1996
    ..Patients who have never achieved a CR and have received three or more chemotherapy regimens do not benefit from high-dose chemotherapy as used in this study...
  14. ncbi request reprint Phase II study of irinotecan and 5-fluorouracil/leucovorin in patients with primary refractory or relapsed advanced oesophageal and gastric carcinoma
    L Assersohn
    Royal Marsden Hospital, London and Sutton, Surrey, UK
    Ann Oncol 15:64-9. 2004
    ..The purpose of this study was to assess the efficacy and toxicity of irinotecan and 5-fluorouracil (5-FU) in primary refractory or relapsed locally advanced or metastatic oesophagogastric (O-G) carcinoma...
  15. pmc Capecitabine and mitomycin C as third-line therapy for patients with metastatic colorectal cancer resistant to fluorouracil and irinotecan
    G Chong
    Department of Medicine, Royal Marsden Hospital, London and Surrey SM2 5PT, UK
    Br J Cancer 93:510-4. 2005
    ..Capecitabine in combination with MMC is an effective regimen for metastatic colorectal cancer resistant to 5FU and irinotecan with an acceptable toxicity profile and a convenient administration schedule...
  16. pmc A phase II trial of preoperative chemotherapy with epirubicin, cisplatin and capecitabine for patients with localised gastro-oesophageal junctional adenocarcinoma
    N Starling
    Department of Medicine, Royal Marsden Hospital NHS Foundation Trust, Sutton, Surrey, UK
    Br J Cancer 100:1725-30. 2009
    ..Although associated with a low pCR rate, survival with ECX was comparable with published studies suggesting that pCR may not correlate with satisfactory outcome from preoperative chemotherapy for localised oesophageal adenocarcinoma...
  17. doi request reprint Matuzumab plus epirubicin, cisplatin and capecitabine (ECX) compared with epirubicin, cisplatin and capecitabine alone as first-line treatment in patients with advanced oesophago-gastric cancer: a randomised, multicentre open-label phase II study
    S Rao
    Gastrointestinal Unit, Royal Marsden Hospital, London and Surrey, UK
    Ann Oncol 21:2213-9. 2010
    ..The aim was to evaluate the efficacy of matuzumab plus ECX versus ECX alone...
  18. doi request reprint Long-term outcome of autologous stem-cell transplantation in relapsed or refractory Hodgkin's lymphoma
    B Sirohi
    Lymphoma Unit, Royal Marsden Hospital and Institute of Cancer Research, Sutton, Surrey, UK
    Ann Oncol 19:1312-9. 2008
    ..The purpose of this study was to assess prognostic factors and outcome of patients with relapsed/refractory Hodgkin's lymphoma (HL) who received high-dose chemotherapy and autologous stem-cell transplant (ASCT)...
  19. ncbi request reprint Mitomycin C, carboplatin and protracted venous infusion 5-fluorouracil in advanced oesophago-gastric and pancreatic cancer: results of two phase II studies
    M Kelleher
    Royal Marsden Hospital, London, UK
    Clin Oncol (R Coll Radiol) 15:92-7. 2003
    ..This combination merits further evaluation with modification of the dose and schedule of carboplatin and MMC in order to reduce the severity of haematological toxicity...
  20. pmc Bcl-2 expression and response to chemotherapy in colorectal adenocarcinomas
    H J Schneider
    The Gastrointestinal Unit, Department of Medicine, Royal Marsden Hospital, Sutton, Surrey, UK
    Br J Cancer 75:427-31. 1997
    ..In the group of patients receiving 5-fluorouracil-based chemotherapy bcl-2 expression did not influence response to chemotherapy; nor did it effect failure-free or overall survival...
  21. doi request reprint A phase I study of sunitinib in combination with FOLFIRI in patients with untreated metastatic colorectal cancer
    N Starling
    Department of Medicine, Royal Marsden Hospital, NHS Foundation Trust, London and Sutton, UK
    Ann Oncol 23:119-27. 2012
    ..v. and l-leucovorin 200 mg/m2 given over 120 min on day 1, followed by 5-FU 400 mg/m2 bolus and then 2400 mg/m2 infused over 46 h) in untreated metastatic colorectal cancer (mCRC)...
  22. doi request reprint A multicentre study of capecitabine, oxaliplatin plus bevacizumab as perioperative treatment of patients with poor-risk colorectal liver-only metastases not selected for upfront resection
    R Wong
    Department of Medicine, Royal Marsden Hospital NHS Foundation Trust, Sutton, UK
    Ann Oncol 22:2042-8. 2011
    ..This study aimed to evaluate perioperative CAPOX (capecitabine-oxaliplatin) plus bevacizumab in patients with poor-risk CLM not selected for upfront resection...
  23. pmc Long-term survival after epirubicin, cisplatin and fluorouracil for gastric cancer: results of a randomized trial
    J S Waters
    Cancer Research Campaign, Section of Medicine and Gastrointestinal Unit, Royal Marsden Hospital and Institute of Cancer Research, Sutton, Surrey, UK
    Br J Cancer 80:269-72. 1999
    ..The probability of long-term survival following surgical resection of residual disease is increased by this treatment. The high response rates seen with ECF support its use in the neoadjuvant setting...
  24. pmc Phase I study of irinotecan and raltitrexed in patients with advanced gastrointestinal tract adenocarcinoma
    H E Ford
    Department of Medicine, CRC Centre for Cancer Therapeutics, Institute of Cancer Research, Sutton, Surrey, UK
    Br J Cancer 83:146-52. 2000
    ..This combination is active with manageable toxicity. Recommended doses for further evaluation are irinotecan 350 mg m(-2) and raltitrexed 3.0 mg m(-2)...
  25. pmc Gemcitabine, cisplatin and methylprednisolone (GEM-P) is an effective salvage regimen in patients with relapsed and refractory lymphoma
    M Ng
    Department of Medicine, Royal Marsden Hospital, Surrey, UK
    Br J Cancer 92:1352-7. 2005
    ..Grade 3 or 4 nonhaematological toxicity was minimal and stem cell mobilisation was not inhibited. GEM-P is an effective salvage regimen and its use prior to autologous stem cell transplant warrants further investigation...
  26. pmc Phase II study of capecitabine and mitomycin C as first-line treatment in patients with advanced colorectal cancer
    S Rao
    Department of Medicine, Royal Marsden Hospital, Downs Road, Sutton, Surrey SM2 5PT, UK
    Br J Cancer 91:839-43. 2004
    ..3%. Capecitabine and MMC have shown encouraging activity with a favourable toxicity profile, a convenient administration schedule, and could be considered for patients deemed unsuitable for oxaliplatin and irinotecan combinations...
  27. pmc Gastrazole (JB95008), a novel CCK2/gastrin receptor antagonist, in the treatment of advanced pancreatic cancer: results from two randomised controlled trials
    I Chau
    Department of Medicine, Royal Marsden Hospital, Downs Road, Sutton, Surrey SM2 5PT, and University College London Hospitals, UK
    Br J Cancer 94:1107-15. 2006
    ..However, it did not produce survival advantage over PVI 5-FU. Lack of toxicity for gastrazole may allow its combination with cytotoxic drugs...
  28. pmc Defining patient outcomes in stage IV colorectal cancer: a prospective study with baseline stratification according to disease resectability status
    D J Watkins
    Department of Medicine, Royal Marsden Hospital, London and Surrey, UK
    Br J Cancer 102:255-61. 2010
    ..In a phase II study primarily designed to assess the efficacy of capecitabine and oxaliplatin, we were able to prospectively examine the outcomes of patients with stage IV colorectal cancer according to the baseline resectability status...
  29. doi request reprint Rechallenge with platinum plus fluoropyrimidine +/- epirubicin in patients with oesophagogastric cancer
    A F C Okines
    Department of Medicine, The Royal Marsden Hospital, London, UK
    Oncology 79:150-8. 2010
    ..The aim of this retrospective study was to evaluate survival following rechallenge with platinum plus fluoropyrimidine (PF) +/- epirubicin...
  30. pmc EPIC: an effective low toxicity regimen for relapsing lymphoma
    T Hickish
    Lymphoma Unit, Royal Marsden Hospital, Sutton, Surrey, London, UK
    Br J Cancer 68:599-604. 1993
    ..The EPIC regimen has equivalent activity to other reported cisplatin based regimens used in the treatment of recurrent lymphoma, but is associated with lower treatment related morbidity and mortality...
  31. ncbi request reprint An oxaliplatin-based chemotherapy in patients with relapsed or refractory intermediate and high-grade non-Hodgkin's lymphoma
    I Chau
    Department of Medicine, Royal Marsden Hospital, Downs Road, Sutton, Surrey SM2 5PT, UK
    Br J Haematol 115:786-92. 2001
    ..It has clinically significant activity with an acceptable toxicity profile. Lack of renal toxicity makes DHAX an attractive cytoreductive regimen before high-dose chemotherapy...
  32. ncbi request reprint Efficacy and tolerability of chemotherapy in elderly patients with advanced oesophago-gastric cancer: A pooled analysis of three clinical trials
    M Trumper
    Section of Medicine, Gastrointestinal Unit, Royal Marsden Hospital, Downs Road, Sutton, Surrey SM2 5PT, United Kingdom
    Eur J Cancer 42:827-34. 2006
    ..Patients > or =70 years with OGC obtained similar benefits from palliative chemotherapy with respect to symptomatic response, tumour regression and survival, without increased toxicities...
  33. doi request reprint Bevacizumab with peri-operative epirubicin, cisplatin and capecitabine (ECX) in localised gastro-oesophageal adenocarcinoma: a safety report
    A F C Okines
    Department of Medicine, The Royal Marsden Hospital NHS Foundation Trust London and Surrey SM2 5PT, London
    Ann Oncol 24:702-9. 2013
    ..Peri-operative chemotherapy and surgery is a standard treatment of localised oesophagogastric adenocarcinoma; however, the outcomes remain poor...
  34. pmc Cediranib with mFOLFOX6 vs bevacizumab with mFOLFOX6 in previously treated metastatic colorectal cancer
    D Cunningham
    Medical Oncology, Royal Marsden Hospital, 15 Cotswold Road, Sutton, Surrey SM2 5NG, UK
    Br J Cancer 108:493-502. 2013
    ..Bevacizumab is an anti-VEGF-A monoclonal antibody with clinical benefit in previously treated metastatic colorectal cancer (mCRC)...
  35. pmc Kirsten ras mutations in patients with colorectal cancer: the 'RASCAL II' study
    H J Andreyev
    Department of Medicine and Therapeutics, Imperial College School of Medicine, Chelsea and Westminster Hospital, 369 Fulham Road, London, SW10 9NH, UK
    Br J Cancer 85:692-6. 2001
    ....
  36. pmc CA19-9 as a prognostic factor in inoperable pancreatic cancer: the implication for clinical trials
    N R Maisey
    Department of Medicine, Royal Marsden Hospital, Sutton, Surrey, UK
    Br J Cancer 93:740-3. 2005
    ..A fall of 20% in CA19-9 level from baseline was an independent prognostic factor for OS (HR 1.9; 95% CI: 1.1-3.4, P = 0.019)...
  37. pmc Influence of metastatic site as an additional predictor for response and outcome in advanced colorectal carcinoma
    L Assersohn
    The Department of Medicine, Royal Marsden Hospital, Sutton, UK
    Br J Cancer 79:1800-5. 1999
    ..Site of metastasis can predict for response to 5FU-based chemotherapy and patients should be stratified according to the involved site of metastasis in the future...
  38. doi request reprint A randomized phase II study of PEP02 (MM-398), irinotecan or docetaxel as a second-line therapy in patients with locally advanced or metastatic gastric or gastro-oesophageal junction adenocarcinoma
    A C Roy
    Department of Medicine, The Royal Marsden Hospital, Sutton, UK
    Ann Oncol 24:1567-73. 2013
    ..This randomized phase II study evaluated the efficacy and safety of single agent PEP02 compared with irinotecan or docetaxel in the second-line treatment of advanced oesophago-gastric (OG) cancer...
  39. pmc The role of pre-treatment diffusion-weighted MRI in predicting long-term outcome of colorectal liver metastasis
    H H Tam
    Department of Radiology, Royal Marsden Hospital, Sutton, UK
    Br J Radiol 86:20130281. 2013
    ..To determine the prognostic value of pre-treatment apparent diffusion coefficient (ADC) of colorectal liver metastases in predicting disease response, progression-free survival (PFS) and overall survival (OS)...
  40. pmc Correlation of bevacizumab-induced hypertension and outcome in the BOXER study, a phase II study of capecitabine, oxaliplatin (CAPOX) plus bevacizumab as peri-operative treatment in 45 patients with poor-risk colorectal liver-only metastases unsuitable fo
    A Dewdney
    Department of Medicine, Royal Marsden Hospital, Downs Road, Sutton, Surrey SM2 5PT, UK
    Br J Cancer 106:1718-21. 2012
    ..The development of bevacizumab-induced arterial hypertension has recently been suggested as a potential predictive biomarker...
  41. pmc Analysis of the time course and prognostic factors determining toxicity due to infused fluorouracil
    N C Tebbutt
    Gastrointestinal Unit, Royal Marsden Hospital, London and Surrey, UK
    Br J Cancer 88:1510-5. 2003
    ..Reduction of infused 5FU dose should be considered for these patients. Such an approach could both reduce severe toxicity owing to chemotherapy and minimise treatment delays, and should be evaluated prospectively...
  42. pmc Surgery with curative-intent in patients treated with first-line chemotherapy plus bevacizumab for metastatic colorectal cancer First BEAT and the randomised phase-III NO16966 trial
    A Okines
    Department of Medicine, The Royal Marsden Hospital NHS Foundation Trust, Sutton, Surrey, UK
    Br J Cancer 101:1033-8. 2009
    ..Complete resection of metastases can result in cure for selected patients with metastatic colorectal cancer...
  43. doi request reprint The impact of carcinoembryonic antigen flare in patients with advanced colorectal cancer receiving first-line chemotherapy
    A S Strimpakos
    Department of Medicine, Royal Marsden Hospital, London and Surrey, UK
    Ann Oncol 21:1013-9. 2010
    ..This study aimed to evaluate the incidence of CEA flare and its impact on objective response rate (ORR), progression-free survival (PFS) and overall survival (OS)...
  44. doi request reprint The use of 18F-FDG PET/CT in colorectal liver metastases--comparison with CT and liver MRI
    G Kong
    Department of Nuclear Medicine and PET, The Royal Marsden NHS Foundation Trust, Downs Road, Sutton, Surrey SM2 5PT, UK
    Eur J Nucl Med Mol Imaging 35:1323-9. 2008
    ....
  45. pmc Antisense treatment directed against mutated Ki-ras in human colorectal adenocarcinoma
    H J Andreyev
    Department of Medicine, Royal Marsden Hospital, London, UK
    Gut 48:230-7. 2001
    ..CONCLUSIONS: Successful targeting of the clinically relevant Ki-ras point mutation with antisense oligonucleotides is difficult because of RNA structure at the mutated site and is inefficient compared with other sites on the Ki-ras mRNA...
  46. ncbi request reprint EXPERT-C: A randomized phase II European multicenter trial of neoadjuvant chemotherapy (capecitabine/oxaliplatin) and chemoradiation (CRT) with or without cetuximab followed by total mesorectal excision (TME) in patients with MRI-defined high-risk rectal
    A Dewdney
    The Royal Marsden Hospital, Surrey, United Kingdom The Royal Marsden Hospital, Sutton, United Kingdom Vall d Hebron University Hospital, Barcelona, Spain Akademiska University Hospital, Uppsala, Sweden Hospital Clinico Universitario, Valencia, Spain The Royal Marsden Hospital NHS Foundation Trust, London, United Kingdom Institute of Cancer Research, Surrey, United Kingdom
    J Clin Oncol 29:360. 2011
    ..This trial evaluates the addition of the anti-EGFR antibody cetuximab to this treatment strategy. KRAS and BRAF mutations have been established as predictive for lack of response to anti-EGFR therapy in metastatic colorectal cancer...
  47. pmc Phase III study of 5FU, etoposide and leucovorin (FELV) compared to epirubicin, cisplatin and 5FU (ECF) in previously untreated patients with advanced biliary cancer
    S Rao
    Department of Medicine, Royal Marsden Hospital, Downs Road, Sutton, Surrey SM2 5PT, UK
    Br J Cancer 92:1650-4. 2005
    ..ECF did not improve OS compared to FELV, but was associated with less acute toxicity. These data suggest that chemotherapy can prolong OS and achieve good symptomatic relief in advanced biliary cancer...
  48. pmc Toxicity associated with capecitabine plus oxaliplatin in colorectal cancer before and after an institutional policy of capecitabine dose reduction
    R Baird
    Department of Medicine, Royal Marsden Hospital, London and Surrey, UK
    Br J Cancer 104:43-50. 2011
    ..Capecitabine plus oxaliplatin (CAPOX) is an established treatment option in colorectal cancer, but can be associated with severe toxicities...
  49. doi request reprint Utility of the Follicular Lymphoma International Prognostic Index and the International Prognostic Index in assessing prognosis and predicting first-line treatment efficacy in follicular lymphoma patients
    V Formica
    Department of Medicine, Royal Marsden Hospital, London and Sutton, UK
    Acta Haematol 122:193-9. 2009
    ..The aim of this study was to validate on this respect the FLIPI system in an independent cohort and compare it with the International Prognostic Index (IPI) used for aggressive lymphomas...
  50. doi request reprint Preoperative high-resolution magnetic resonance imaging can identify good prognosis stage I, II, and III rectal cancer best managed by surgery alone: a prospective, multicenter, European study
    Fiona G M Taylor
    Mayday University Hospital, Croydon, Surrey, UK
    Ann Surg 253:711-9. 2011
    ..To assess local recurrence, disease-free survival, and overall survival in magnetic resonance imaging (MRI)-predicted good prognosis tumors treated by surgery alone...
  51. ncbi request reprint A randomized trial of chemoradiation using mitomycin or cisplatin, with or without maintenance cisplatin/5FU in squamous cell carcinoma of the anus (ACT II)
    R James
    Maidstone General Hospital, Maidstone, United Kingdom Cancer Research UK and UCL Cancer Trials Centre, London, United Kingdom Mount Vernon Hospital, Northwood, United Kingdom St James s University Hospital, Leeds, United Kingdom St Mark s Hospital, London, United Kingdom The Royal Marsden Hospital, London, United Kingdom
    J Clin Oncol 27:LBA4009. 2009
    ..This trial addresses two questions: whether (i) replacing MMC with cisplatin (CDDP) improves the complete response (CR) rate, and (ii) two cycles of maintenance chemotherapy after CRT reduces recurrence...
  52. ncbi request reprint Oxaliplatin and capecitabine chemotherapy for advanced colorectal cancer: a single institution's experience
    K Sumpter
    Department of Medicine, Royal Marsden Hospital, London and Surrey, London, UK
    Clin Oncol (R Coll Radiol) 15:221-6. 2003
    ..To determine the efficacy of the combination of oxaliplatin and capecitabine in patients with advanced colorectal cancer...
  53. pmc Docetaxel combined with irinotecan or 5-fluorouracil in patients with advanced oesophago-gastric cancer: a randomised phase II study
    A Roy
    Department of Medicine, Royal Marsden Hospital, Sutton, London, SM25PT, UK
    Br J Cancer 107:435-41. 2012
    ..This randomised phase II study evaluated the efficacy and toxicity profile of two non-platinum docetaxel-based doublet regimens in advanced oesophago-gastric cancer...
  54. ncbi request reprint Mucinous histology predicts for reduced fluorouracil responsiveness and survival in advanced colorectal cancer
    F V Negri
    Department of Medicine, Department of Histopathology, Royal Marsden Hospital, London and Sutton, Surrey, UK
    Ann Oncol 16:1305-10. 2005
    ..The purpose of this study was to investigate specifically the efficacy of fluorouracil-based first-line chemotherapy in patients with advanced mucinous CRC...
  55. pmc Cost-effectiveness analysis of cetuximab/irinotecan vs active/best supportive care for the treatment of metastatic colorectal cancer patients who have failed previous chemotherapy treatment
    N Starling
    Royal Marsden Hospital, Sutton, Surrey, UK
    Br J Cancer 96:206-12. 2007
    ..However, this result should be considered in the context of a number of factors specific to the treated patient population...
  56. pmc The prognostic role of WHO classification, urinary 5-hydroxyindoleacetic acid and liver function tests in metastatic neuroendocrine carcinomas of the gastroenteropancreatic tract
    V Formica
    Department of Medicine, Royal Marsden Hospital, London and Sutton, Surrey, UK
    Br J Cancer 96:1178-82. 2007
    ....
  57. ncbi request reprint Gefitinib and irinotecan in patients with fluoropyrimidine-refractory, irinotecan-naive advanced colorectal cancer: a phase I-II study
    I Chau
    Department of Medicine, Royal Marsden Hospital, Downs Road, London and Surrey, Sutton, Surrey, UK
    Ann Oncol 18:730-7. 2007
    ..To establish the recommended dose level (RDL) and to evaluate the efficacy and safety of gefitinib plus irinotecan in patients with advanced fluoropyrimidine-refractory colorectal cancer (CRC)...
  58. ncbi request reprint Phase III trial of 5-fluorouracil and leucovorin plus either 3H1 anti-idiotype monoclonal antibody or placebo in patients with advanced colorectal cancer
    G Chong
    Royal Marsden Hospital, Sutton, Surrey, UK
    Ann Oncol 17:437-42. 2006
    ..It therefore has the potential, via the anti-idiotypic network, to stimulate immune responses to CEA that may benefit colorectal cancer patients...
  59. pmc Outcome of follicular lymphoma grade 3: is anthracycline necessary as front-line therapy?
    I Chau
    Department of Medicine, Royal Marsden Hospital, Downs Road, Sutton, Surrey SM2 5PT, UK
    Br J Cancer 89:36-42. 2003
    ..Anthracyclines did not appear to influence survival or disease relapses when given as front-line therapy in our series. The role of anthracyclines should be further evaluated in large randomised studies...
  60. pmc Idiopathic pneumonia syndrome after high-dose chemotherapy for relapsed Hodgkin's disease
    C Rubio
    The Cancer Research Campaign Section of Medicine, The Royal Marsden Hospital, Sutton, Surrey, UK
    Br J Cancer 75:1044-8. 1997
    ..If < 475 mg m(-2) is given, even patients with previous mantle radiotherapy and/or previous bleomycin have a very low risk of developing fatal lung toxicity if lung function tests are normal...
  61. ncbi request reprint A randomised study of protracted venous infusion of 5-fluorouracil (5-FU) with or without bolus mitomycin C (MMC) in patients with carcinoma of unknown primary
    L Assersohn
    Department of Medicine, Royal Marsden Hospital, Downs Road, Sutton, Surrey SM2 5PT, UK
    Eur J Cancer 39:1121-8. 2003
    ..PVI 5-FU may be a potential reference regimen in randomised trials with newer chemotherapy agents in patients with CUP...
  62. pmc Mature results from three large controlled studies with raltitrexed ('Tomudex')
    D Cunningham
    The Royal Marsden Hospital, Sutton, UK
    Br J Cancer 77:15-21. 1998
    ..In particular, patients receiving raltitrexed may benefit from the minimization or avoidance of mucositis, and both patients and healthcare providers may find the convenient administration schedule of the drug advantageous...
  63. ncbi request reprint REAL3: A multicenter randomized phase II/III trial of epirubicin, oxaliplatin, and capecitabine (EOC) versus modified (m) EOC plus panitumumab (P) in advanced oesophagogastric (OG) cancer-Response rate (RR), toxicity, and molecular analysis from phase II
    I Chau
    The Royal Marsden Hospital, London and Surrey, United Kingdom The Royal Marsden Hospital, Sutton, United Kingdom The Institute of Cancer Research, London, United Kingdom The Royal Marsden Hospital NHS Foundation Trust, London and Surrey, United Kingdom The Royal Marsden Hospital NHS Foundation Trust, London, United Kingdom Royal Marsden Hospital, London, United Kingdom The Institute of Cancer Research, Sutton, United Kingdom Northern Centre for Cancer Care, Newcastle upon Tyne, United Kingdom St Lukes Cancer Centre, Guildford, United Kingdom Russells Hall Hospital, Dudley, United Kingdom Velindre Hospital NHS Trust, Cardiff, United Kingdom Nottingham University Hospitals NHS Trust, Nottingham, United Kingdom Weston Park, Sheffield, United Kingdom Kent Oncology Centre, Maidstone, United Kingdom Mount Vernon Cancer Centre, Middlesex, United Kingdom St James s Hospital, Leeds, United Kingdom Conquest Hospital, Hastings, United Kingdom Clatterbridge Centre for Oncology NHS Foundation Trust, Wirral, United Kingdom Royal Marsden Hospital, Sutton, United Kingdom
    J Clin Oncol 29:4131. 2011
    ..J Clin Oncol 2010)...
  64. pmc Neoadjuvant systemic fluorouracil and mitomycin C prior to synchronous chemoradiation is an effective strategy in locally advanced rectal cancer
    I Chau
    Department of Medicine, Royal Marsden Hospital, Sutton, Surrey, UK
    Br J Cancer 88:1017-24. 2003
    ..Neoadjuvant systemic chemotherapy as a prelude to synchronous chemoradiation can be administered with negligible risk of disease progression and produces considerable symptomatic response with associated tumour regression...
  65. doi request reprint Patupilone in patients with pretreated metastatic/locally recurrent colorectal cancer: results of the Phase II CINATRA trial
    S Y Moorcraft
    The Royal Marsden, Downs Road, Sutton, SM2 5PT, UK
    Invest New Drugs 31:1339-44. 2013
    ..Phase I trials of the microtubule stabilising agent patupilone showed encouraging tumour control and response rates in patients with metastatic colorectal cancer...
  66. pmc Intestinal complications after chemotherapy for patients with unresected primary colorectal cancer and synchronous metastases
    N C Tebbutt
    Gastrointestinal Unit, Royal Marsden Hospital, London and Surrey, UK
    Gut 52:568-73. 2003
    ..The role of palliative resection of the primary tumour in patients who present with metastatic colorectal cancer is unclear...
  67. doi request reprint Meta-analysis of the REAL-2 and ML17032 trials: evaluating capecitabine-based combination chemotherapy and infused 5-fluorouracil-based combination chemotherapy for the treatment of advanced oesophago-gastric cancer
    A F C Okines
    The Royal Marsden Hospital NHS Foundation Trust, Sutton, Surrey, UK
    Ann Oncol 20:1529-34. 2009
    ....
  68. pmc Survival from cancer of the stomach in England and Wales up to 2001
    S Rao
    Department of Medicine, Royal Marsden Hospital, Downs Road, Sutton, Surrey SM2 5PT, UK
    Br J Cancer 99:S19-20. 2008
  69. ncbi request reprint Baseline quality of life predicts survival in patients with advanced colorectal cancer
    N R Maisey
    Department of Medicine, Royal Marsden Hospital, Downs Road, Sutton, Surrey SM2 5PT, UK
    Eur J Cancer 38:1351-7. 2002
    ..0001). Baseline QoL is a strong independent predictor of survival in patients with advanced colorectal cancer. Measurements should be routinely recorded in clinical trials to stratify cohorts and aid in trial comparison...
  70. ncbi request reprint A multicentre phase II trial of primary chemotherapy with cisplatin and protracted venous infusion 5-fluorouracil followed by chemoradiation in patients with carcinoma of the oesophagus
    J S Waters
    Cancer Research Campaign Section of Medicine and Gastrointestinal Unit, Royal Marsden Hospital and Institute of Cancer Research, Sutton, Surrey
    Ann Oncol 13:1763-70. 2002
    ..We undertook a multicentre phase II trial to evaluate the safety and efficacy of primary chemotherapy followed by chemoradiation for localised adenocarcinoma or squamous carcinoma of the oesophagus...
  71. ncbi request reprint Chemotherapy for primary gastric lymphoma: does in-patient observation prevent complications?
    N Maisey
    Department of Medicine, Royal Marsden Hospital, London, UK
    Clin Oncol (R Coll Radiol) 16:48-52. 2004
    ..As a result, several units, including our own, have routinely admitted all patients for observation during the commencement of therapy. We conducted an audit to elucidate the incidence and timing of such complications...
  72. ncbi request reprint Lung cancer after Hodgkin's disease: a nested case-control study of the relation to treatment
    A J Swerdlow
    Section of Epidemiology, Academic Unit of Radiotherapy and Oncology, Royal Marsden Hospital, and Royal Marsden National Health Service Trust, Sutton, Surrey, United Kingdom
    J Clin Oncol 19:1610-8. 2001
    ..The role of chemotherapy in the etiology of lung cancer after Hodgkin's disease deserves further investigation...
  73. ncbi request reprint Treatment of mantle-cell lymphoma with Rituximab (chimeric monoclonal anti-CD20 antibody): analysis of factors associated with response
    J M Foran
    ICRF Medical Oncology Unit, St Bartholomew s Hospital, London, UK
    Ann Oncol 11:117-21. 2000
    ....
  74. ncbi request reprint ESMO Minimum Clinical Recommendations for diagnosis, treatment and follow-up of gastric cancer
    D Cunningham
    The Royal Marsden Hospital, Downs Road, Sutton, Surrey SM2 5PT, UK
    Ann Oncol 16:i22-3. 2005
  75. ncbi request reprint Predictive factors of survival in patients with advanced colorectal cancer: an individual data analysis of 602 patients included in irinotecan phase III trials
    E Mitry
    CHU Ambroise Pare, AP HP, Boulogne Billancourt
    Ann Oncol 15:1013-7. 2004
    ..Irinotecan combined with these regimens increases survival in front-line treatment. Irinotecan also improves survival in second-line treatment...
  76. pmc Oral capecitabine vs intravenous 5-fluorouracil and leucovorin: integrated efficacy data and novel analyses from two large, randomised, phase III trials
    E Van Cutsem
    University Hospital Gasthuisberg, Leuven, Belgium
    Br J Cancer 90:1190-7. 2004
    ..Capecitabine is a suitable replacement for i.v. 5-FU as the backbone of colorectal cancer therapy...
  77. doi request reprint Detection of colorectal hepatic metastases using MnDPDP MR imaging and diffusion-weighted imaging (DWI) alone and in combination
    D M Koh
    Cancer Research UK Clinical Magnetic Resonance Research Group, Institute of Cancer Research, Sutton, UK
    Eur Radiol 18:903-10. 2008
    ..5). Combination of MnDPDP MR imaging and DWI resulted in the highest diagnostic accuracy and can increase sensitivity without loss in specificity...
  78. ncbi request reprint Raltitrexed: current clinical status and future directions
    E Van Cutsem
    Department of Internal Medicine, University Hospital Gasthuisberg, Leuven, Belgium
    Ann Oncol 13:513-22. 2002
    ..Of particular interest is the combination of raltitrexed and oxaliplatin, which has shown promising antitumour effects in first-line treatment of advanced CRC and malignant mesothelioma, a disease that is refractory to chemotherapy...
  79. pmc Elderly patients with fluoropyrimidine and thymidylate synthase inhibitor-resistant advanced colorectal cancer derive similar benefit without excessive toxicity when treated with irinotecan monotherapy
    I Chau
    Royal Marsden Hospital, London and Surrey, UK
    Br J Cancer 91:1453-8. 2004
    ..Elderly patients derive the same benefit without experiencing more toxicity with second-line irinotecan treatment for advanced CRC. Our data do not support the recommendation to reduce the starting dose for the elderly patients...
  80. ncbi request reprint Efficacy, tolerability and management of raltitrexed (Tomudex) monotherapy in patients with advanced colorectal cancer. a review of phase II/III trials
    D Cunningham
    GI Unit, The Royal Marsden Hospital, Surrey, Sutton, UK
    Eur J Cancer 38:478-86. 2002
    ....
  81. ncbi request reprint Efficacy of 5-fluorouracil-based chemotherapy in elderly patients with metastatic colorectal cancer: a pooled analysis of clinical trials
    G Folprecht
    University Hospital, Dresden, Germany
    Ann Oncol 15:1330-8. 2004
    ....
  82. ncbi request reprint A multicentre, randomised phase III trial comparing protracted venous infusion (PVI) 5-fluorouracil (5-FU) with PVI 5-FU plus mitomycin C in patients with inoperable oesophago-gastric cancer
    N C Tebbutt
    Royal Marsden Hospital, London and Surrey, UK
    Ann Oncol 13:1568-75. 2002
    ..This randomised study compared protracted venous infusion (PVI) fluorouracil (5-FU) with PVI 5-FU plus mitomycin C (MMC) in patients with advanced oesophago-gastric cancer...
  83. ncbi request reprint Inhibition of Kirsten-ras expression in human colorectal cancer using rationally selected Kirsten-ras antisense oligonucleotides
    P J Ross
    Cancer Research Campaign Centre for Cancer Therapeutics, Institute of Cancer Research, 15 Cotswold Road, Sutton, Surrey, SM2 5NG, United Kingdom
    Mol Cancer Ther 1:29-41. 2001
    ....
  84. ncbi request reprint Adjuvant treatment of colorectal cancer (current expert opinion derived from the Third International Conference: Perspectives in Colorectal Cancer, Dublin, 2001)
    E Van Cutsem
    Department Internal Medicine, University Hospital Gasthuisberg, Herestraat 49, 3000, Leuven, Belgium
    Eur J Cancer 38:1429-36. 2002
    ....
  85. pmc Clinical and economic benefits of irinotecan in combination with 5-fluorouracil and folinic acid as first line treatment of metastatic colorectal cancer
    D Cunningham
    Department of Medicine, Royal Marsden NHS Trust, Davis Road, Sutton, Surrey SM2 5PT, UK
    Br J Cancer 86:1677-83. 2002
    ....
  86. ncbi request reprint Systemic treatment of colorectal cancer
    N C Tebbutt
    Department of Medicine, Royal Marsden Hospital, Downs Road, Sutton, Surrey, UK
    Eur J Cancer 38:1000-15. 2002
    ....
  87. ncbi request reprint Prospective randomized trial comparing mitomycin, cisplatin, and protracted venous-infusion fluorouracil (PVI 5-FU) With epirubicin, cisplatin, and PVI 5-FU in advanced esophagogastric cancer
    P Ross
    Department of Medicine and Gastrointestinal Unit, Royal Marsden Hospital, London and Sutton, Surrey, United Kingdom
    J Clin Oncol 20:1996-2004. 2002
    ....
  88. ncbi request reprint Clinical determinants of survival in patients with 5-fluorouracil-based treatment for metastatic colorectal cancer: results of a multivariate analysis of 3825 patients
    C H Kohne
    Medizinische Klinik und Poliklinik I, Universit├Ątsklinikum Carl Gustav Carus der TU Dresden, Germany
    Ann Oncol 13:308-17. 2002
    ..A multivariate analysis was performed in order to identify predictors and their constellation that allow a valid prediction of the outcome in patients treated with 5-fluorouracil (5-FU)-based therapy...
  89. pmc Alpha-interferon does not increase the efficacy of 5-fluorouracil in advanced colorectal cancer
    P Thirion
    Department of Radiotherapy, Saint Luke s Hospital, Dublin 6, Ireland
    Br J Cancer 84:611-20. 2001
    ..We conclude that alpha-IFN does not increase the efficacy of 5FU or of 5FU + LV, and that 5FU + alpha-IFN is significantly inferior to 5FU + LV, for patients with advanced colorectal cancer...
  90. pmc A phase II trial of the vitamin D analogue Seocalcitol (EB1089) in patients with inoperable pancreatic cancer
    T R J Evans
    CRC Department of Medical Oncology, Beatson Oncology Centre, Western Infirmary, Dumbarton Road, Glasgow G11 6NT, UK
    Br J Cancer 86:680-5. 2002
    ..Further studies are necessary to determine if this agent has any cytostatic activity in this malignancy in minimal disease states...
  91. ncbi request reprint A randomised comparison between 6 months of bolus fluorouracil/leucovorin and 12 weeks of protracted venous infusion fluorouracil as adjuvant treatment in colorectal cancer
    I Chau
    Royal Marsden Hospital, London and Surrey
    Ann Oncol 16:549-57. 2005
    ....
  92. ncbi request reprint CT detection of hydronephrosis in resected colorectal cancer: a predictor of recurrent disease
    G Brown
    Department of Diagnostic Radiology, Royal Marsden Hospital, London, UK
    Clin Radiol 58:137-42. 2003
    ..To investigate the causes and significance of hydronephrosis in follow-up of colorectal cancer...
  93. ncbi request reprint The role of surveillance CT scans in patients with diffuse large B-cell non-Hodgkin's lymphoma
    A E Guppy
    Department of Medicine, Royal Marsden Hospital, London, UK
    Leuk Lymphoma 44:123-5. 2003
    ..Routine surveillance CT scans are of limited value in detecting asymptomatic early relapse and other approaches are required in order to identify patients destined to relapse at an earlier stage...
  94. ncbi request reprint Tumour vaccine associated lymphadenopathy and false positive positron emission tomography scan changes
    R L Jones
    Gastrointestinal Department, Royal Marsden Hospital, Down s Road, Sutton, Surrey SM2 5PT, UK
    Br J Radiol 77:74-5. 2004
    ..This appearance should be considered as a possible false positive in patients undergoing such treatment who are being investigated with PET scans...
  95. ncbi request reprint The role of intrathecal chemotherapy prophylaxis in patients with diffuse large B-cell lymphoma
    H T Arkenau
    Department of Medical Oncology, Royal Marsden Hospital, London and Sutton, UK
    Ann Oncol 18:541-5. 2007
    ..This single centre retrospective study investigated the rate of CNS relapse in patients with DLBCL who received standardised intrathecal (IT) chemoprophylaxis...
  96. ncbi request reprint Emerging therapies for rectal cancer
    Y J Chua
    Royal Marsden Hospital, Sutton, Surrey, UK
    Colorectal Dis 8:18-20. 2006
    ..Whilst these remain experimental, it is likely that these will serve as a platform for developing an expanded range of treatment options so that clinicians will be better able to tailor treatment to the needs of different patients...
  97. ncbi request reprint Phase III double-blind placebo-controlled study of farnesyl transferase inhibitor R115777 in patients with refractory advanced colorectal cancer
    S Rao
    Royal Marsden Hospital, Downs Rd, Sutton, Surrey SM2 5PT, United Kingdom
    J Clin Oncol 22:3950-7. 2004
    ..To determine whether R115777 improves survival in patients with refractory advanced colorectal cancer (CRC) in a multicenter, double-blind, prospective randomized study...
  98. pmc A phase III trial comparing CHOP to PMitCEBO with or without G-CSF in patients aged 60 plus with aggressive non-Hodgkin's lymphoma
    C Burton
    University College London and CRUK Clinical Trials Centre, 222 Euston Road, London NW1 2DA, UK
    Br J Cancer 94:806-13. 2006
    ..There was no significant difference in the failure-free, progression-free or overall survival with the addition of G-CSF...
  99. ncbi request reprint Definition of disease-free survival: this is my truth-show me yours
    Y J Chua
    Ann Oncol 16:1719-21. 2005
  100. pmc Fludarabine, adriamycin and dexamethasone (FAD) in newly diagnosed advanced follicular lymphoma: a phase II study by the British National Lymphoma Investigation (BNLI)
    L Yung
    Department of Haematology, University College London, UK
    Br J Cancer 91:695-8. 2004
    ..The high response rate has not translated into major improvements in failure-free survival and consideration must be given to alternative treatment modalities to consolidate the high rate of initial responses...
  101. ncbi request reprint Phase II study of ISIS 3521, an antisense oligodeoxynucleotide to protein kinase C alpha, in patients with previously treated low-grade non-Hodgkin's lymphoma
    S Rao
    Royal Marsden Hospital, London, UK
    Ann Oncol 15:1413-8. 2004
    ..The purpose of this study was to assess the efficacy and safety of ISIS 3521, an antisense phosphorothioate oligonucleotide to protein kinase C alpha in patients with relapsed low-grade non-Hodgkin's lymphoma (NHL)...